Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
7 reports, 5 independent
Updated Aug 25
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 7
- Developments
- 4
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Sub-event
Moderna and Merck are advancing Intismeran trials and developing new cancer treatments while facing patent cliff risks.1 source
- Positive Phase 3 data announced from the combined treatment trials involving Moderna and Merck.Sub-event
Personalized mRNA cancer vaccine Intismeran developed, causing Moderna shares to surge.1 source
Keep exploring
Part of
Moderna and Merck personalized cancer vaccine advancementAlso in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.